38 terminated. 38 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 38 | Terminated 38 |
| Phase 2 | 11 | Terminated 11 |
Follow Respiratory Hypersensitivity: new trials by email Literature Review of Respiratory Hypersensitivity trials Research Report on Respiratory Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma Briquilimab, Placebo Comparator - Allergic Asthma | Phase 1 | Terminated | Jasper Therapeutics, Inc. | 17 | 2024-11-26 | 2025-09-16 |
| Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis Mometasone + Azelastine, Mometasone Furoate, Azelastine Hydrochloride - Seasonal Allergic Rhinitis | Phase 1 | Terminated | Sandoz | 38 | 2023-06-08 | 2023-09-28 |
| To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis TQC3564 tablets, Placebo tablets, TQC3564 tablets, montelukast sodium tablets - Allergic Rhinitis | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 12 | 2022-09-14 | 2024-11-26 |
| Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease ARO-MUC5AC, Placebo - Asthma, Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Terminated | Arrowhead Pharmaceuticals | 78 | 2022-06-27 | 2026-09-14 |
| Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma Albuterol Sulfate, Interferon gamma-primed mesenchymal stromal cells (MSCs), Prednisone - Asthma | Phase 1 | Terminated | Emory University | 1 | 2022-03-16 | 2025-06-03 |
| Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma Zavegepant, Placebo - Asthma | Phase 1 | Terminated | Pfizer | 45 | 2021-10-18 | 2024-07-19 |
| First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 LQ036, Matching Placebo - Asthma | Phase 1 | Terminated | Syneos Health | 40 | 2021-09-06 | 2023-04-13 |
| A Trial of SHR-1703 in Healthy Subjects SHR-1703, Placebo - Asthma | Phase 1 | Terminated | Atridia Pty Ltd. | 1 | 2021-06-14 | 2021-12-01 |
| Evaluation of AZD8154 Concentrations in Blood AZD8154 nebuliser, AZD8154 Monodose DPI presented in capsules, AZD8154 Placebo Monodose DPI presented in capsules - Asthma | Phase 1 | Terminated | AstraZeneca | 10 | 2020-07-17 | 2021-08-24 |
| A Study of MRx-4DP0004 in Asthma MRx-4DP0004, Placebo - Asthma | Phase 1 | Terminated | 4D pharma plc | 34 | 2019-07-04 | 2024-04-17 |
| Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma Roflumilast, Placebo - Asthma | Phase 1 | Terminated | University of California, Davis | 5 | 2019-01-21 | 2023-10-24 |
| Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide - Chronic Obstructive Pulmonary Disease, Asthma | Phase 1 | Terminated | Chiesi Farmaceutici S.p.A. | 19 | 2019-01-14 | 2022-05-06 |
| Trial of Tauroursodeoxycholic Acid (TUDCA) in Asthma Tauroursodeoxycholic Acid - Asthma | Phase 1 | Terminated | University of Vermont | 11 | 2019-01-10 | 2019-09-16 |
| Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma hMSCs - Asthma | Phase 1 | Terminated | Marilyn Glassberg | 3 | 2017-06-22 | 2020-05-21 |
| A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of AZD9898 AZD9898, Matching Placebo - Asthma | Phase 1 | Terminated | AstraZeneca | 34 | 2017-05-10 | 2018-01-17 |
| Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections Dose Level 1, Dose Level 2, Placebo - Allergic Conjunctivitis, Allergic Rhinitis | Phase 1 | Terminated | Woodmont Pharmaceuticals, Inc. | 2 | 2017-03-30 | 2018-02-26 |
| Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals RP3128, Placebo - Healthy Volunteers, Asthma | Phase 1 / Phase 2 | Terminated | Rhizen Pharmaceuticals SA | 57 | 2016-11-03 | 2019-10-04 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153 RV6153 single dose, RV6153 matching placebo single dose, RV6153 14 day repeat dose - Asthma, Healthy Volunteers | Phase 1 | Terminated | Respivert Ltd | 55 | 2015-07-01 | 2016-03-04 |
| Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma JNJ-43260295, Placebo, Nasal Allergen Challenge - Healthy, Asthma | Phase 1 | Terminated | Janssen Research & Development, LLC | 17 | 2014-10-01 | 2016-03-23 |
| Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients HollisterStier, Normal saline - Allergic Rhinitis | Phase 1 | Terminated | Gachon University Gil Medical Center | 24 | 2014-08-01 | 2016-08-11 |
Showing 20 of 38. Sign in to see all of them.
Asthma (32) · Hypersensitivity (4) · Rhinitis, Allergic (4) · Pulmonary Disease, Chronic Obstructive (2) · Aspergillosis, Allergic Bronchopulmonary (1) · Bronchial Diseases (1) · Chronic Disease (1) · Conjunctivitis, Allergic (1) · Cystic Fibrosis (1) · Dyspnea (1) · Gastroesophageal Reflux (1) · Hyperinsulinism (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Lung Diseases (1)
Hypersensitivity, Immediate (37) · Immune System Diseases (37) · Respiratory Tract Diseases (37) · Hypersensitivity (34) · Lung Diseases (32) · Bronchial Diseases (31) · Lung Diseases, Obstructive (31) · Nose Diseases (5) · Otorhinolaryngologic Diseases (5) · Rhinitis (5) · Pathological Conditions, Signs and Symptoms (4) · Disease Attributes (3) · Pathologic Processes (3) · Chronic Disease (2)
Epinephrine (2) · Prednisolone (2) · ASM-024 (1) · Albuterol (1) · Antigens, Dermatophagoides (1) · BASS2 protein, Arabidopsis (1) · Bronchoscopy (1) · Capsules (1) · Esomeprazole (1) · Interferon-gamma (1) · Lipopolysaccharides (1) · Magnetic Resonance Imaging (1) · Mometasone Furoate (1) · Phenol (1) · Prednisone (1)
GlaxoSmithKline (3) · Amphastar Pharmaceuticals, Inc. (2) · AstraZeneca (2) · John Sundy (2) · 4D pharma plc (1) · Amgen (1) · Anergis (1) · Arrowhead Pharmaceuticals (1) · Asmacure Ltée (1) · Atridia Pty Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chiesi Farmaceutici S.p.A. (1) · Emory University (1) · Emphycorp (1) · Gachon University Gil Medical Center (1)
United States (18) · United Kingdom (9) · Canada (6) · Australia (3) · Germany (2) · South Korea (2) · Belgium (1) · China (1) · France (1) · Ireland (1) · New Zealand (1) · Panama (1) · Poland (1) · Romania (1) · Spain (1)
Alessio Fasano, M. D. (1) · Christopher Brightling, Professor (1) · Christopher O'Brien, MD, PhD, FCCP (1) · Dave Singh (1) · David Kaminsky, MD (1) · Donald Tashkin, M.D. (1) · Dr Richard Friend (1) · Edwin Horwitz, MD (1) · Emily Schoemmell (1) · Francois Spertini, MD (1) · Huaiyu Gu (1) · Jim Shi, M.D., Ph.D. (1) · John S Sundy, M.D., PhD (1)
PMID 29550052, PMID 32150492, PMID 33293212, PMID 33314326, PMID 35128939
2015 (1), 2017 (1), 2023 (1), P01AT002647 (1), R21AT004089 (1)